DOWNLOAD: The lines between pharma and biotech are blurring. https://vist.ly/54tjr As funding tightens and policy shifts, both sectors are adapting, with biotechs becoming leaner and more independent, and pharma exploring new business models and direct-to-patient channels. Convenience, affordability, and access are now as important as innovation. Check out the article at the link in this post.
Evaluate Ltd
Information Services
Evaluate provides trusted commercial intelligence and predictive analytics to the pharmaceutical industry
About us
Evaluate provides trusted commercial intelligence and forecasting models for the pharmaceutical industry. We help our clients to refine and transform their understanding of the past, present and future of the global biopharma market to drive better decisions. Evaluate solutions give you the time and confidence to turn understanding into insight, and insight into action. Evaluate Pharma - the trusted global view of the pharmaceutical market’s past, present and future performance with consensus forecasts to 2030, company financials, pipelines, deals and more. Evaluate Omnium - provides a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, delivering game-changing insight into pharma asset potential. Forecasting Solutions - Ensure precise and efficient forecasting at every stage of your product lifecycle. Our comprehensive suite of forecasting solutions tailored to the pharmaceutical industry, including software, cloud-based platforms, custom-built models, advanced analytics and data. Our forecasting solutions support forecasters through new product planning, launch, and commercialisation. CDMO Intelligence - Access CDMO screening, molecular landscape insights, detailed manufacturing capabilities, and accurate volume forecasts. You’ll have a wealth of data and industry insights at your fingertips, backed by gold standard financial forecast methodologies. Consulting and Analytics - Evaluate’s consulting and analytics team is here to help clients address unique scientific, clinical and commercial challenges. We answer key asset, portfolio strategy, and corporate strategy-related business questions, powered by the combined resources of Norstella, one of the world’s largest pharma intelligence solutions providers. Evaluate’s combination of leading data sources, deep pharma expertise, robust methodologies, data science and real-world data will ensure your teams make the right decisions to drive your growth.
- Website
-
http://www.evaluate.com
External link for Evaluate Ltd
- Industry
- Information Services
- Company size
- 51-200 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 1996
- Specialties
- pharma business analysis, pharma licensing deals, pharma consensus forecasts, biotech business analysis, pharma competitive intelligence, medtech consensus forecasts, pharma business developement, pharma R&D analysis, pharma data, pharma forecasting models, Real World Data, Pharma portfolio strategy, Pharma Consulting, and BD&L consulting
Locations
-
Primary
Get directions
3 More London Riverside
London, SE1 2RE, GB
-
Get directions
1 Pennsylvania Plaza
#2505
New York, NY 10119, US
-
Get directions
Akasaka Garden City 4F, 4-15-1 Akasaka,
Tokyo, Tokyo 107-0052, JP
Employees at Evaluate Ltd
Updates
-
Most teams are still making critical portfolio decisions with incomplete or internally biased forecasts. That is where value gets lost. Evaluate Advisory helps you quantify real commercial opportunity with independent, evidence-backed forecasting and valuation: • Market sizing across geographies and patient populations • Scenario-based NPV and rNPV modeling • Clear, defensible assumptions for investors and partners Stop second-guessing asset value. Start making confident, data-driven decisions. Find out more about our consulting & Analytics team: https://vist.ly/54q9c
-
FDA oversight remains an important consideration in orphan drug outlooks. Melanie Senior and Andreas Hadjivasiliou discuss how regulatory factors are incorporated into projections through 2032 in "Orphan Drugs: A safe(r) passage amid stormy waters?" View the on‑demand webinar here: https://vist.ly/54nrt
-
The biggest outlook in pharma is back. https://vist.ly/54jmd If you are making decisions in today’s market, you cannot afford to miss this. Registration is now open for the World Preview 2026 webinar, featuring extended forecasts to 2032 and the insights you need to stay ahead. 📅 June 16 | 3pm London | 10am New York Register now: https://vist.ly/54jmd
-
-
Biopharma deal-making did not slow down in 2025. It evolved. https://vist.ly/54ihk Total alliance value hit $269.5B, with larger, more strategic partnerships driving a 37% increase in average deal size. M&A value surged to $201.2B, fueled by a handful of mega deals reshaping the market. Q4 led the charge across alliances, M&A, and financing. Momentum is building, not cooling. Get the full breakdown of deal structures, quarterly trends, and where capital is flowing next.
-
-
The biggest M&A deals don’t just reflect the market; they define it. https://vist.ly/54i5u Q1 2026 saw a late surge in biopharma dealmaking, with multiple billion-dollar acquisitions reshaping portfolios and pipelines. From oncology to rare diseases, the top five deals signal where strategic bets are being placed next. Download the report to see what’s driving the biggest moves.
-
-
The orphan drug market is shifting faster than expected, and the next decade is set to reshape the entire rare disease landscape. https://vist.ly/54i44 Our report highlights: - A dramatic expansion in long‑term revenue potential - Market share growth that outpaces many traditional therapy areas - A wave of high‑value assets emerging as future category leaders - New entrants disrupting the competitive order in the rare disease From forecast growth to competitive reshuffles, there’s a lot changing, and the big numbers might surprise you.
-
The World Preview 2026 webinar is now open for registration, and this year, we’re going further than ever before, with forecasts extended out to 2032. https://lnkd.in/eyqxBwt8 In a market shaped by uncertainty from patent cliffs to pricing pressure and shifting deal activity, getting a clear view of the future has never been more critical. Join: 🔹 Daniel Chancellor, VP Thought Leadership, Norstella 🔹 Melanie Senior, World Preview author and industry expert Together, they’ll unpack: ✔ The future top 10 companies and drugs ✔ Market growth and key therapeutic areas ✔ Top pipeline products and the blockbusters of the future ✔ The continuing rise of China and what it means for the US and Europe 📅 June 16 | 3pm LDN | 10am NY Don’t miss your chance to hear the insights shaping pharma’s future. Register now: https://lnkd.in/eyqxBwt8
-
2026 is shaping up to be a big year for pharma, but who’s leading the charge? https://vist.ly/54a3v From biotech’s resurgence to the top-selling drugs and biggest companies, we’ve pulled together the key forecasts you need to know. Swipe through for a snapshot of what’s ahead, then download the full 2026 Preview Report for deeper insights.
-
Q1 2026 biopharma: momentum is back… but caution is still driving decisions. https://vist.ly/545sx - M&A up 32% QoQ with a late-quarter surge - IPOs hit $1.81B, but momentum faded by March - VC steady at $7.94B, shifting toward mid-sized rounds Capital is available. But it is being deployed more selectively than ever. Download the full Q1 report to see where conviction is building.
-